Showing results (131-140 of 408) with videos related to

Sort By:
Pageof 41
American Journal of Hematology|April 7, 2017
Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphomaMoritz Binder, Megan M O'Byrne, Matthew J Maurer, et al.
Cancer|March 6, 2002
Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphomaGregory A Wiseman, Bryan Leigh, William D Erwin, et al.
American Journal of Hematology|May 15, 2014
The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvementAmie E Jackson, Jacob P Smeltzer, Thomas M Habermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patientsStephen M Ansell, Susan M Geyer, Matthew J Maurer, et al.
American Journal of Hematology|August 29, 2014
Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphomaMohamad B Sonbol, Matthew J Maurer, Mary J Stenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myelomaS Vincent Rajkumar, Paul G Richardson, Martha Q Lacy, et al.
Blood|September 17, 2011
Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activitySherine F Elsawa, Anne J Novak, Steven C Ziesmer, et al.
British Journal of Haematology|July 10, 2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantationJulie M Vose, Thomas M Habermann, Myron S Czuczman, et al.
The Lancet. Haematology|July 5, 2016
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trialPatrick B Johnston, Betsy LaPlant, Ellen McPhail, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphomaStephen M Ansell, Thomas E Witzig, David J Inwards, et al.
Pageof 41